

Journal Club Spotlights: Current Advancements in Non-Small Cell Lung Cancer



Key Concepts

ORCHARD

- Continuing osimertinib in combination with datopotamab deruxtecan (Dato-DXd) following progression on frontline osimertinib monotherapy appears clinically beneficial due to continued suppression of EGFR, overcoming resistance mechanisms, and potential enhanced CNS activity.
- Dato-DXd 6mg/kg in combination with osimertinib provides durable and extended responses in patients with advanced/metastatic EGFR positive NSCLC in the second-line setting.